Compare MBNKO & XOMAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Medallion Bank Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock Series G par value $1.00 per share
Current Price
| Metric | MBNKO | XOMAP |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | 142 | 14 |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | N/A |
| Metric | MBNKO | XOMAP |
|---|---|---|
| Price | $25.70 | $25.51 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.9K | 1.6K |
| Earning Date | N/A | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.61 | $25.14 |
| 52 Week High | $28.00 | $27.30 |
| Indicator | MBNKO | XOMAP |
|---|---|---|
| Relative Strength Index (RSI) | 54.72 | 50.10 |
| Support Level | $25.34 | $25.19 |
| Resistance Level | $25.87 | $25.60 |
| Average True Range (ATR) | 0.14 | 0.08 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 63.83 | 71.87 |
Medallion Bank is engaged in providing consumer loans, raising deposits, and managing other banking activities. It offers affordable financing for home improvement contractors, including window, siding, and roof replacements; kitchen, bath, and basement remodels; HVAC (Heating Ventilation and Air Conditioning), and solar PV installations. Medallion also offers recreation financing for new and used motorhomes, towable RVs, truck campers, cargo trailers, utility trailers, horse trailers, and a variety of ATVs and other power sport vehicles. Its segments are Recreation, Home Improvement, and Other. The bank generates maximum revenue from the Recreation segment.
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates. The Company's drug royalty aggregator business is mainly focused on the acquisition of early to mid-stage clinical assets. Geographically, the company operates in Switzerland, the United States, Asia Pacific, Europe, and other regions.